Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 14/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HPGDS | O60760 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21354683 | 0.93 | BRD4 (0.38) | IDH1MCHR1MEN1KMT2AABL1 | |
| SCHEMBL30315331 | 0.93 | BRD4 (0.38) | IDH1MCHR1MEN1KMT2AABL1 | |
| SCHEMBL21354586 | 0.91 | MCHR1 (0.37) | IDH1MCHR1MEN1KMT2A | |
| SCHEMBL30315330 | 0.91 | MCHR1 (0.37) | IDH1MCHR1MEN1KMT2A | |
| SCHEMBL20111113 | 0.89 | ACSS2 (0.38) | IDH1MCHR1MEN1KMT2A | |
| SCHEMBL18791928 | 0.89 | ACSS2 (0.38) | IDH1MCHR1MEN1KMT2A | |
| SCHEMBL18791929 | 0.89 | ACSS2 (0.38) | IDH1MCHR1MEN1KMT2A | |
| SCHEMBL21354758 | 0.89 | HPGDS (0.37) | IDH1MCHR1HPGDSABL1 | |
| SCHEMBL18779284 | 0.86 | PDE2A (0.32) | PDE2A | |
| SCHEMBL18791667 | 0.85 | CSNK1D (0.42) | MCHR1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2023-08-15 | — | — | US | disclosed |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | CHANNEL BIOSCIENCES, LLC | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11724990-B2 | Kv7 channel activators compositions and methods of use | KCNA7, KCNK17, KCNAB1 | IDH1 2551/4885MCHR1 3930/4885ROCK2 3519/4885 |
| US-20170114022-A1 | BENZOIMIDAZOL-1,2-YL AMIDES AS Kv7 CHANNEL ACTIVATORS | KCNA7, KCNJ2, KCNK17 | IDH1 3023/4885MCHR1 4581/4885ROCK2 3789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.